Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers
NCT04901078Phase 1Completed
- Sponsor
- Kinoxis Therapeutics
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in opioid use disorder (OUD) comparing Active (KNX100) with Placebo (2 arms). Primary endpoint: Proportion of Participants With Treatment-Emergent Adverse Events. Started Apr 2022; status: completed.
02
Drugs
KNX100
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04901078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901078.